These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 28988934)

  • 1. Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study.
    Weiss KH; Askari FK; Czlonkowska A; Ferenci P; Bronstein JM; Bega D; Ala A; Nicholl D; Flint S; Olsson L; Plitz T; Bjartmar C; Schilsky ML
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):869-876. PubMed ID: 28988934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WTX101 - an investigational drug for the treatment of Wilson disease.
    Weiss KH; Członkowska A; Hedera P; Ferenci P
    Expert Opin Investig Drugs; 2018 Jun; 27(6):561-567. PubMed ID: 29806946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial.
    Schilsky ML; Czlonkowska A; Zuin M; Cassiman D; Twardowschy C; Poujois A; Gondim FAA; Denk G; Cury RG; Ott P; Moore J; Ala A; D'Inca R; Couchonnal-Bedoya E; D'Hollander K; Dubois N; Kamlin COF; Weiss KH;
    Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1092-1102. PubMed ID: 36183738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
    Brewer GJ; Askari F; Dick RB; Sitterly J; Fink JK; Carlson M; Kluin KJ; Lorincz MT
    Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical recommendations and new therapies for Wilson's disease.
    Brewer GJ
    Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
    Brewer GJ
    Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The onset of psychiatric disorders and Wilson's disease].
    Benhamla T; Tirouche YD; Abaoub-Germain A; Theodore F
    Encephale; 2007 Dec; 33(6):924-32. PubMed ID: 18789784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate) in a rat model of Wilson disease.
    Plitz T; Boyling L
    Xenobiotica; 2019 Mar; 49(3):332-338. PubMed ID: 29460662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analyzing the Therapeutic Efficacy of Bis-Choline-Tetrathiomolybdate in the
    Kim P; Zhang CC; Thoröe-Boveleth S; Buhl EM; Weiskirchen S; Stremmel W; Merle U; Weiskirchen R
    Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study.
    Marcellini M; Di Ciommo V; Callea F; Devito R; Comparcola D; Sartorelli MR; Carelli G; Nobili V
    J Lab Clin Med; 2005 Mar; 145(3):139-43. PubMed ID: 15871305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers for diagnosis of Wilson's disease.
    Ryan A; Nevitt SJ; Tuohy O; Cook P
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31743430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.
    Brewer GJ; Askari F; Lorincz MT; Carlson M; Schilsky M; Kluin KJ; Hedera P; Moretti P; Fink JK; Tankanow R; Dick RB; Sitterly J
    Arch Neurol; 2006 Apr; 63(4):521-7. PubMed ID: 16606763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and prognosis of early diagnosed Wilson's disease: A large cohort study.
    Li S; Lin Y; Chen S; Zhang W; Chen YM; Lu X; Shao Y; Lu Z; Sheng H; Guan Z; Zheng R; Liang C; Chen Y; Liu L; Zeng C
    Liver Int; 2024 Sep; 44(9):2424-2433. PubMed ID: 38847512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The treatment of Wilson's disease, a rare genetic disorder of copper metabolism.
    Purchase R
    Sci Prog; 2013; 96(Pt 1):19-32. PubMed ID: 23738435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients.
    Brewer GJ; Dick RD; Johnson V; Wang Y; Yuzbasiyan-Gurkan V; Kluin K; Fink JK; Aisen A
    Arch Neurol; 1994 Jun; 51(6):545-54. PubMed ID: 8198464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.
    Morita J; Yoshino M; Watari H; Yoshida I; Motohiro T; Yamashita F; Okano Y; Hashimoto T
    Dev Pharmacol Ther; 1992; 19(1):6-9. PubMed ID: 1307347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial therapy of patients with Wilson's disease with tetrathiomolybdate.
    Brewer GJ; Dick RD; Yuzbasiyan-Gurkin V; Tankanow R; Young AB; Kluin KJ
    Arch Neurol; 1991 Jan; 48(1):42-7. PubMed ID: 1986725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease.
    Stuerenburg HJ
    J Neural Transm (Vienna); 2000; 107(3):321-9. PubMed ID: 10821440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice.
    Hoogenraad TU
    Brain Dev; 2006 Apr; 28(3):141-6. PubMed ID: 16466879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease.
    Kirk FT; Munk DE; Swenson ES; Quicquaro AM; Vendelbo MH; Larsen A; Schilsky ML; Ott P; Sandahl TD
    J Hepatol; 2024 Apr; 80(4):586-595. PubMed ID: 38081365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.